In their study of FRA in lung adenocarcinoma, O'Shannessy et al employed rigorous validation of a potentially useful clinical tool--using an immunohistochemical assay with a specific monoclonal antibody, they show that FRA expression is relatively specific for lung adenocarcinoma and that high FRA expression is associated with improved survival. The gene discussed is FOLR1; the disease is lung adenocarcinoma.